SK282907B6 - Potravinový doplnok a jeho použitie - Google Patents

Potravinový doplnok a jeho použitie Download PDF

Info

Publication number: SK282907B6
Authority: SK; Slovakia
Prior art keywords: carnitine; acid; acetyl; propionyl; food supplement
Prior art date: 1997-04-01

Application number

SK1349-99A

Other languages

English (en)

Slovak (sk)

Other versions

SK134999A3 (en

Inventor

Claudio Cavazza

Original Assignee

Sigma-Tau Healthscience S. P. A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-01

Filing date

1998-03-27

Publication date

2003-01-09

1998-03-27 Application filed by Sigma-Tau Healthscience S. P. A. filed Critical Sigma-Tau Healthscience S. P. A.

2000-05-16 Publication of SK134999A3 publication Critical patent/SK134999A3/sk

2003-01-09 Publication of SK282907B6 publication Critical patent/SK282907B6/sk

Links

235000015872 dietary supplement Nutrition 0.000 title claims abstract description 30
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 62
UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims abstract description 41
RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 33
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims abstract description 12
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 12
239000004480 active ingredient Substances 0.000 claims abstract description 7
229960003624 creatine Drugs 0.000 claims abstract description 6
239000006046 creatine Substances 0.000 claims abstract description 6
IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims abstract description 6
229950007002 phosphocreatine Drugs 0.000 claims abstract description 6
150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 5
150000003839 salts Chemical class 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 11
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 11
229940024606 amino acid Drugs 0.000 claims description 10
235000001014 amino acid Nutrition 0.000 claims description 10
150000001413 amino acids Chemical class 0.000 claims description 10
239000003797 essential amino acid Substances 0.000 claims description 9
235000020776 essential amino acid Nutrition 0.000 claims description 9
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 6
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 5
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
-1 salts disodium citrate Chemical class 0.000 claims description 5
239000004474 valine Substances 0.000 claims description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
229960001230 asparagine Drugs 0.000 claims description 4
229940009098 aspartate Drugs 0.000 claims description 4
229960005261 aspartic acid Drugs 0.000 claims description 4
229960002989 glutamic acid Drugs 0.000 claims description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
229960000310 isoleucine Drugs 0.000 claims description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
239000011707 mineral Substances 0.000 claims description 4
235000010755 mineral Nutrition 0.000 claims description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
229910019142 PO4 Inorganic materials 0.000 claims description 3
HNSUOMBUJRUZHJ-REVJHSINSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O HNSUOMBUJRUZHJ-REVJHSINSA-N 0.000 claims description 3
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 3
239000001527 calcium lactate Substances 0.000 claims description 3
229960002401 calcium lactate Drugs 0.000 claims description 3
235000011086 calcium lactate Nutrition 0.000 claims description 3
239000002526 disodium citrate Substances 0.000 claims description 3
235000019262 disodium citrate Nutrition 0.000 claims description 3
229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
239000010452 phosphate Substances 0.000 claims description 3
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 2
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 2
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
229930003268 Vitamin C Natural products 0.000 claims description 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
235000009582 asparagine Nutrition 0.000 claims description 2
235000003704 aspartic acid Nutrition 0.000 claims description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
235000013922 glutamic acid Nutrition 0.000 claims description 2
239000004220 glutamic acid Substances 0.000 claims description 2
229960002743 glutamine Drugs 0.000 claims description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
229940043046 isoleucine 50 mg Drugs 0.000 claims description 2
229910052748 manganese Inorganic materials 0.000 claims description 2
239000011572 manganese Substances 0.000 claims description 2
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
230000011667 skeletal muscle adaptation Effects 0.000 claims description 2
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
229940066528 trichloroacetate Drugs 0.000 claims description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
235000019154 vitamin C Nutrition 0.000 claims description 2
239000011718 vitamin C Substances 0.000 claims description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 1
210000002027 skeletal muscle Anatomy 0.000 abstract description 6
230000006978 adaptation Effects 0.000 abstract description 2
239000004615 ingredient Substances 0.000 abstract description 2
208000016254 weariness Diseases 0.000 abstract 1
238000011282 treatment Methods 0.000 description 26
239000000902 placebo Substances 0.000 description 20
229940068196 placebo Drugs 0.000 description 20
230000000694 effects Effects 0.000 description 13
229960004203 carnitine Drugs 0.000 description 10
206010003549 asthenia Diseases 0.000 description 7
230000037396 body weight Effects 0.000 description 6
230000002354 daily effect Effects 0.000 description 6
206010016256 fatigue Diseases 0.000 description 6
235000016709 nutrition Nutrition 0.000 description 6
238000012360 testing method Methods 0.000 description 6
125000002252 acyl group Chemical group 0.000 description 5
238000013461 design Methods 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
229940079593 drug Drugs 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
150000004665 fatty acids Chemical class 0.000 description 5
230000002503 metabolic effect Effects 0.000 description 5
230000037081 physical activity Effects 0.000 description 5
239000000758 substrate Substances 0.000 description 5
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
230000002195 synergetic effect Effects 0.000 description 4
208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000012549 training Methods 0.000 description 4
230000014616 translation Effects 0.000 description 4
201000004569 Blindness Diseases 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 3
102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 3
206010058892 Carnitine deficiency Diseases 0.000 description 3
208000000857 Hepatic Insufficiency Diseases 0.000 description 3
206010019663 Hepatic failure Diseases 0.000 description 3
208000021642 Muscular disease Diseases 0.000 description 3
201000009623 Myopathy Diseases 0.000 description 3
208000012902 Nervous system disease Diseases 0.000 description 3
208000001647 Renal Insufficiency Diseases 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
201000006370 kidney failure Diseases 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
230000002438 mitochondrial effect Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
238000001243 protein synthesis Methods 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000011160 research Methods 0.000 description 3
230000000241 respiratory effect Effects 0.000 description 3
208000013363 skeletal muscle disease Diseases 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000004102 tricarboxylic acid cycle Effects 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
206010007559 Cardiac failure congestive Diseases 0.000 description 2
108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 2
102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 2
208000018522 Gastrointestinal disease Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
102000008934 Muscle Proteins Human genes 0.000 description 2
108010074084 Muscle Proteins Proteins 0.000 description 2
206010067482 No adverse event Diseases 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
108010076625 carnitine octanoyltransferase Proteins 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
150000004668 long chain fatty acids Chemical class 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000036284 oxygen consumption Effects 0.000 description 2
230000036314 physical performance Effects 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
ZKSGPMLZIPWJAF-ODZAUARKSA-N (z)-but-2-enedioic acid;oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)\C=C/C(O)=O ZKSGPMLZIPWJAF-ODZAUARKSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
230000002407 ATP formation Effects 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000019914 Mental Fatigue Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010049816 Muscle tightness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006399 behavior Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
101150081234 ccmB gene Proteins 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
235000017471 coenzyme Q10 Nutrition 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000000385 dialysis solution Substances 0.000 description 1
CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
230000004133 fatty acid degradation Effects 0.000 description 1
230000004129 fatty acid metabolism Effects 0.000 description 1
235000013373 food additive Nutrition 0.000 description 1
239000002778 food additive Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
230000004110 gluconeogenesis Effects 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
150000002576 ketones Chemical group 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000013190 lipid storage Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
239000002075 main ingredient Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
210000001700 mitochondrial membrane Anatomy 0.000 description 1
230000008450 motivation Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000037257 muscle growth Effects 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000037361 pathway Effects 0.000 description 1
238000011056 performance test Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
235000021476 total parenteral nutrition Nutrition 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/80—Geriatric
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/806—Salt or mineral substitute

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nutrition Science (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Obesity (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1349-99A 1997-04-01 1998-03-27 Potravinový doplnok a jeho použitie SK282907B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT97RM000185A IT1291127B1 (it)	1997-04-01	1997-04-01	Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
PCT/IT1998/000069 WO1998043499A2 (en)	1997-04-01	1998-03-27	Nutritional supplement

Publications (2)

Publication Number	Publication Date
SK134999A3 SK134999A3 (en)	2000-05-16
SK282907B6 true SK282907B6 (sk)	2003-01-09

Family

ID=11404926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1349-99A SK282907B6 (sk)	1997-04-01	1998-03-27	Potravinový doplnok a jeho použitie

Country Status (18)

Country	Link
US (1)	US6245378B1 (de)
EP (1)	EP0973415B1 (de)
JP (1)	JP2001517085A (de)
KR (1)	KR20010005865A (de)
CN (1)	CN1074912C (de)
AT (1)	ATE202675T1 (de)
AU (1)	AU729412B2 (de)
BR (1)	BR9807905A (de)
CA (1)	CA2285332C (de)
DE (1)	DE69801047T2 (de)
DK (1)	DK0973415T3 (de)
ES (1)	ES2159179T3 (de)
GR (1)	GR3036777T3 (de)
IL (1)	IL131857A (de)
IT (1)	IT1291127B1 (de)
PT (1)	PT973415E (de)
SK (1)	SK282907B6 (de)
WO (1)	WO1998043499A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2146555B1 (es) *	1999-01-22	2001-03-01	Helsint S A L	Empleo de formulaciones a base de fracciones hidrosolubles de phlebodium decumanum (exply-37) y/o polypodium leucotomos como complemento nutricional en la prevencion y reversion del sindrome de sobresfuerzo fisico.
IT1306173B1 (it)	1999-07-23	2001-05-30	Sigma Tau Healthscience Spa	Composizione per la prevenzione degli affaticamenti muscolari e permigliorare il rendimento energetico muscolare.
IT1306179B1 (it) *	1999-07-28	2001-05-30	Sigma Tau Healthscience Spa	Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale.
WO2001035953A2 (en) *	1999-11-17	2001-05-25	Kuhrts Eric H	Exercise and muscle enhancement formulations
US6914076B2 (en) *	2000-01-19	2005-07-05	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Treating chronic uremic patients undergoing periodical dialysis
US6429230B1 (en) *	2000-01-19	2002-08-06	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Treating chronic uremic patients undergoing periodical dialysis
US6335369B1 (en) *	2000-01-19	2002-01-01	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Treating chronic uremic patients undergoing periodical dialysis
IT1316998B1 (it) *	2000-03-02	2003-05-26	Sigma Tau Healthscience Spa	Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
US8252309B2 (en)	2000-04-04	2012-08-28	Sigma-Tau Industrie Farmaceutiche Riunite Spa	Dietary supplement energy-providing to skeletal muscles
IT1317043B1 (it) *	2000-06-14	2003-05-26	Sigma Tau Healthscience Spa	Integratore alimentare potenziante il metabolismo energeticomuscolare, comprendente una alcanoil l-carnitina e ribosio.
CA2420562C (en) *	2000-09-14	2011-03-29	Board Of Regents Of The University Of Nebraska	Creatine ester pronutrient compounds and formulations
US20030212136A1 (en)	2001-09-14	2003-11-13	Vennerstrom Jonathan L.	Creatine ester pronutrient compounds and formulations
US20020150627A1 (en) *	2001-01-26	2002-10-17	Stout Jeffrey Ray	Composition containing creatine and phosphorus
DE10133200A1 (de) *	2001-07-07	2003-01-23	Beiersdorf Ag	Carnitin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
US6652891B2 (en)	2001-12-12	2003-11-25	Herbasway Laboratories, Llc	Co-enzyme Q10 dietary supplement
ITRM20020194A1 (it) *	2002-04-09	2003-10-09	Sigma Tau Healthscience Spa	Composizione utile per aumentare la concentrazione e la motilita' degli spermatozoi e migliorarne la morfologia nell'uomo.
US7776913B2 (en)	2002-12-13	2010-08-17	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Carnitines for treating or preventing disorders caused by andropause
ITRM20020620A1 (it) *	2002-12-13	2004-06-14	Sigma Tau Ind Farmaceuti	Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
US7288570B2 (en) *	2002-12-20	2007-10-30	Nutricia N.V.	Stimulation of in vivo production of proteins
DE10350140A1 (de) *	2003-03-28	2004-10-14	Martin Schymura	Fruchtgummizusammensetzung
JP2006137746A (ja) *	2004-10-13	2006-06-01	Otsuka Pharmaceut Factory Inc	オレキシン誘導組成物
WO2006092449A2 (en) *	2005-03-02	2006-09-08	Metanomics Gmbh	Process for the production of fine chemicals
US8263137B2 (en)	2005-08-04	2012-09-11	Vertical Pharmaceuticals, Inc.	Nutritional supplement for women
US7998500B2 (en)	2005-08-04	2011-08-16	Vertical Pharmaceuticals, Inc.	Nutritional supplement for women
US8202546B2 (en)	2005-08-04	2012-06-19	Vertical Pharmaceuticals, Inc.	Nutritional supplement for use under physiologically stressful conditions
US7901710B2 (en)	2005-08-04	2011-03-08	Vertical Pharmaceuticals, Inc.	Nutritional supplement for use under physiologically stressful conditions
WO2007056176A2 (en) *	2005-11-03	2007-05-18	Southwest Immunology, Inc.	Compositions for preventing and reducing delayed onset muscle soreness
US20070248648A1 (en) *	2006-04-20	2007-10-25	Next Proteins, Inc.	High protein, fatigue reducing powder
US10435356B1 (en)	2007-09-18	2019-10-08	Thermolife International, Llc	Amino acid compositions
US8466187B2 (en)	2007-09-18	2013-06-18	Thermolife International, Llc	Amino acid compositions
US10646508B1 (en)	2007-09-18	2020-05-12	Thermolife International, Llc	Method of safely administering nitrate dietary supplements and compositions
US10426792B1 (en) *	2007-09-18	2019-10-01	Thermolife International, Llc	Amino acid compositions
US10426750B1 (en)	2007-09-18	2019-10-01	Thermolife International, Llc	Amino acid supplement formulations
CN101524155B (zh) *	2009-04-20	2012-10-10	北京康比特体育科技股份有限公司	一种氨基酸组合物
US12612370B2 (en)	2011-03-02	2026-04-28	Thermolife International, Llc	Amino acid compositions
KR20140019827A (ko) *	2011-04-05	2014-02-17	론자 아게 (론자 엘티디.)	피로를 감소 또는 예방하고 인지 기능을 개선시키기 위한 l-카르니틴, 그의 염 및 유도체의 용도
EP2508179A1 (de) *	2011-04-05	2012-10-10	Lonza Ltd.	Verwendung von L-Carnitin, Salzen und Derivaten davon zur Verringerung oder Vorbeugung von Ermüdung und zur Verbesserung der kognitiven Funktion
CA2833159C (en)	2011-04-13	2019-08-06	Thermolife International, Llc	N-acetyl beta alanine methods of use
CN102512655B (zh) *	2011-11-30	2013-10-30	北京康比特体育科技股份有限公司	左旋肉碱组合物和制剂，及其制备方法和应用
WO2014045065A2 (en) *	2012-09-22	2014-03-27	Bslim Holdings Limited	Dietary compositions and their uses
CN103271350B (zh) *	2013-03-04	2014-09-24	中国航天员科研训练中心	空间站航天员太空高能压缩食品及其制法
GB201304112D0 (en) *	2013-03-07	2013-04-24	Univ Nottingham	Modulation of energy expenditure
CN104415043B (zh) *	2013-09-03	2017-03-15	上海华拓医药科技发展有限公司	一种磷酸肌酸二钠盐在制备抗癌因性疲乏药物中的用途
CA2951567C (en)	2014-06-12	2023-10-31	Lonza, Inc.	Method for decreasing skeletal muscle damage and/or oxidative stress in mammals
BR112018007434A2 (pt)	2015-10-27	2018-10-23	Cytozyme Animal Nutrition Inc	composições para nutrição animal, usos e métodos relacionados
US10674746B2 (en)	2015-10-27	2020-06-09	Cytozyme Animal Nutrition, Inc.	Animal nutrition compositions and related methods
EP3389385A1 (de) *	2015-12-18	2018-10-24	Lonza Inc.	Verfahren und zusammensetzung zur erhöhung der muskelproteinsynthese und/oder funktionalen stärke bei säugetieren sowie verfahren zur herstellung einer zusammensetzung
TWI732309B (zh) *	2018-10-10	2021-07-01	蘇娥梁	補虛損保健品組合物及其製備方法和其應用
JP2024541338A (ja)	2020-11-12	2024-11-08	サーモライフインターナショナル，エルエルシー	血中酸素飽和度を増大させる方法
US11865139B2 (en)	2020-11-12	2024-01-09	Thermolife International, Llc	Method of treating migraines and headaches
AU2022220004A1 (en)	2021-02-11	2023-08-17	Thermolife International, Llc	A method of administering nitric oxide gas
WO2022215085A1 (en) *	2021-04-06	2022-10-13	Celagenex Research (India) Pvt. Ltd.	A synergistic composition for potentiating stabilized atp
CN118638020B (zh) *	2024-08-08	2024-11-19	杭州海尔希畜牧科技有限公司	L-天门冬氨酸l(-)肉碱(1:1)的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4400371A (en) *	1972-11-06	1983-08-23	Biocarn Ltd.	Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
FR2384751A1 (fr) *	1977-03-23	1978-10-20	Francaise Coop Pharma	Nouveaux derives de la taurine a activite neuro-musculaire renforcee
AU518617B2 (en) *	1977-04-29	1981-10-08	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Therapeutic application of acetyl-d, 1-carnitine
DE2903558C2 (de) *	1978-02-03	1994-09-01	Sigma Tau Ind Farmaceuti	Verwendung von L-Carnitin
IT1156769B (it) *	1978-05-25	1987-02-04	Sigma Tau Ind Farmaceuti	Applicazione terapeutica della carnitina e di altri acil derivati della carnitina
IT1206954B (it) *	1979-02-12	1989-05-17	Sigma Tau Ind Farmaceuti	Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
US4346107A (en) *	1979-02-12	1982-08-24	Claudio Cavazza	Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1119853B (it) *	1979-09-21	1986-03-10	Sigma Tau Ind Farmaceuti	Composizione farmaceutica comprendente l-carnitina per il trattamento delle dislipidemie ed iperlipo proteinemie
IT1119854B (it) *	1979-09-21	1986-03-10	Sigma Tau Ind Farmaceuti	Composizione farmaceutica comprendente l-carnitina per il trattamento di disfunzioni cardiache
IT1120033B (it) *	1979-10-05	1986-03-19	Sigma Tau Ind Farmaceuti	Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
IT1142934B (it) *	1981-11-06	1986-10-15	Sigma Tau Ind Farmaceuti	Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
IT1157238B (it) *	1982-10-29	1987-02-11	Sigma Tau Ind Farmaceuti	Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
CH655005A5 (it) *	1983-02-16	1986-03-27	Sigma Tau Ind Farmaceuti	Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
EP0150688B1 (de) *	1983-12-28	1987-04-22	Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.	Salze von L-Carnitin und Alkanoyl-L-Carnitinen sowie Verfahren zur Herstellung derselben
DE3420828A1 (de) *	1984-06-05	1985-12-05	Bayer Ag, 5090 Leverkusen	Fungizide mittel
US4604286A (en) *	1984-09-17	1986-08-05	Daigo Nutritive Chemicals, Ltd.	Infusion solution for parenteral nutrition
IT1196564B (it) *	1986-08-04	1988-11-16	Sigma Tau Ind Farmaceuti	Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
ATE88631T1 (de)	1986-09-17	1993-05-15	Clintec Nutrition Co	Zusatznahrung bzw. therapie fuer personen mit risiko oder in behandlung fuer arteriosklerotische vaskulaere, kardiovaskulaere und/oder thrombotische erkrankungen.
IT1245699B (it) *	1991-05-29	1994-10-14	Sigma Tau Ind Farmaceuti	Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
IT1258491B (it)	1992-09-24	1996-02-26	Sigma Tau Ind Farmaceuti	Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
US5817329A (en) *	1997-02-28	1998-10-06	Gardiner; Paul T.	Nutritional supplement for increased muscle size and strength for body builders

1997
- 1997-04-01 IT IT97RM000185A patent/IT1291127B1/it active IP Right Grant
1998
- 1998-03-27 EP EP98912704A patent/EP0973415B1/de not_active Expired - Lifetime
- 1998-03-27 US US09/147,179 patent/US6245378B1/en not_active Expired - Lifetime
- 1998-03-27 DK DK98912704T patent/DK0973415T3/da active
- 1998-03-27 KR KR1019997008941A patent/KR20010005865A/ko not_active Withdrawn
- 1998-03-27 WO PCT/IT1998/000069 patent/WO1998043499A2/en not_active Ceased
- 1998-03-27 JP JP54137898A patent/JP2001517085A/ja active Pending
- 1998-03-27 DE DE69801047T patent/DE69801047T2/de not_active Expired - Lifetime
- 1998-03-27 BR BR9807905-0A patent/BR9807905A/pt not_active IP Right Cessation
- 1998-03-27 PT PT98912704T patent/PT973415E/pt unknown
- 1998-03-27 CN CN98803848A patent/CN1074912C/zh not_active Expired - Fee Related
- 1998-03-27 ES ES98912704T patent/ES2159179T3/es not_active Expired - Lifetime
- 1998-03-27 SK SK1349-99A patent/SK282907B6/sk unknown
- 1998-03-27 AU AU67462/98A patent/AU729412B2/en not_active Expired
- 1998-03-27 IL IL13185798A patent/IL131857A/en not_active IP Right Cessation
- 1998-03-27 CA CA002285332A patent/CA2285332C/en not_active Expired - Lifetime
- 1998-03-27 AT AT98912704T patent/ATE202675T1/de active
2001
- 2001-10-03 GR GR20010401638T patent/GR3036777T3/el unknown

Also Published As

Publication number	Publication date
US6245378B1 (en)	2001-06-12
ITRM970185A1 (it)	1998-10-01
AU6746298A (en)	1998-10-22
DK0973415T3 (da)	2001-09-24
CN1074912C (zh)	2001-11-21
JP2001517085A (ja)	2001-10-02
EP0973415A2 (de)	2000-01-26
GR3036777T3 (en)	2002-01-31
PT973415E (pt)	2001-10-30
ATE202675T1 (de)	2001-07-15
ES2159179T3 (es)	2001-09-16
WO1998043499A2 (en)	1998-10-08
BR9807905A (pt)	2000-02-22
DE69801047D1 (de)	2001-08-09
AU729412B2 (en)	2001-02-01
WO1998043499A3 (en)	1999-01-07
KR20010005865A (ko)	2001-01-15
IL131857A0 (en)	2001-03-19
IT1291127B1 (it)	1998-12-29
IL131857A (en)	2002-04-21
DE69801047T2 (de)	2001-10-31
HK1026124A1 (en)	2000-12-08
EP0973415B1 (de)	2001-07-04
CN1251496A (zh)	2000-04-26
CA2285332C (en)	2007-11-27
CA2285332A1 (en)	1998-10-08
SK134999A3 (en)	2000-05-16

Publication	Publication Date	Title
SK282907B6 (sk)	2003-01-09	Potravinový doplnok a jeho použitie
US6159942A (en)	2000-12-12	Compositions for increasing energy in vivo
US5817329A (en)	1998-10-06	Nutritional supplement for increased muscle size and strength for body builders
US6534480B2 (en)	2003-03-18	Compositions for increasing energy in vivo
US8518455B2 (en)	2013-08-27	Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
HUP0202298A2 (en)	2002-10-28	Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise
US8207109B2 (en)	2012-06-26	Food supplement with a slimming effect
AU750645B2 (en)	2002-07-25	Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH
BRPI0617487A2 (pt)	2011-07-26	suplemento dietÉtico que proporciona energia aos mésculos esquelÉticos e protege o aparelho cardiovascular
HUP0201727A2 (en)	2002-09-28	Dietary supplement energy-providing to skeletal muscles and protecting the cardiovascular tract
CA2400959C (en)	2011-01-04	Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q10
MXPA99008999A (en)	2000-02-02	Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals
CZ347999A3 (cs)	2000-02-16	Doplňková výživa pro snazší adaptaci kosterního svalstva vyčerpaného zatěžujícími výkony a paralyzování únavy asthenických jedinců
HK1026124B (en)	2002-04-19	Nutritional supplement
EP1745789A1 (de)	2007-01-24	Ribose enthaltende Zubereitungen zur Erhöhung der Energy in vivo
Braverman	0	The Healing Nutrients Within (Volume 2 of 2)(EasyRead Large Bold Edition)
RU2001101529A (ru)	2002-12-20	Композиция, включающая карнитин и глутатион, пригодная для повышения всасывания глутатиона и усиливающая его эффекты